Pharmaceutical expansion into emerging markets presents a paradox of opportunity and risk. While demographic growth, epidemiological transitions, and rising healthcare expenditure make these markets attractive, high uncertainty surrounding regulatory variability, fragmented distribution systems, price sensitivity, and demand unpredictability create substantial launch risks. Conventional pharmaceutical launch models rely heavily on retrospective market analysis and static forecasting methods that insufficiently capture dynamic market signals. This study proposes a Predictive Launch Architecture that integrates artificial intelligence-driven market intelligence, real-time data streams, adaptive demand forecasting, and strategic risk modeling to improve launch precision and reduce commercial failure probability. Using mixed method modeling, simulation analytics, and comparative performance assessment across representative emerging markets, the research demonstrates how machine learning algorithms, predictive epidemiology, digital sentiment analytics, and supply chain intelligence collectively enhance launch readiness and portfolio resilience. Findings indicate that AI-enabled predictive architectures can reduce forecast error, accelerate regulatory navigation, optimize pricing strategies, and improve distribution efficiency. The framework contributes a scalable decision intelligence model for multinational pharmaceutical firms seeking risk-adjusted expansion into volatile markets. The study advances strategic marketing science, pharmaceutical operations management, and digital transformation scholarship while offering practical pathways for safer therapeutic access in developing economies.